In preclinical colon cancer mouse models, Partial PARPi inhibition with metronomic therapy, such as olaparib and talazoparib, has been demonstrated to reactivate antitumor immunity through increases in intratumoral T-cell function and cytotoxicity, thus enhancing anti-PD-1 immunotherapy (106). Here, PDCD1 is linked to colonic neoplasm.